Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001
-
Shares outstanding
-
67.8M
-
Number of holders
-
178
-
Total 13F shares, excl. options
-
72.7M
-
Shares change
-
-1.05M
-
Total reported value, excl. options
-
$1.48B
-
Value change
-
-$19M
-
Put/Call ratio
-
2.43
-
Number of buys
-
111
-
Number of sells
-
-69
-
Price
-
$20.35
Significant Holders of Celldex Therapeutics, Inc. - Common Stock, par value $0.001 (CLDX) as of Q2 2025
217 filings reported holding CLDX - Celldex Therapeutics, Inc. - Common Stock, par value $0.001 as of Q2 2025.
Celldex Therapeutics, Inc. - Common Stock, par value $0.001 (CLDX) has 178 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 72.7M shares
.
Largest 10 shareholders include Kynam Capital Management, LP (6.1M shares), BlackRock, Inc. (5.55M shares), FMR LLC (5.44M shares), WELLINGTON MANAGEMENT GROUP LLP (5.23M shares), VANGUARD GROUP INC (3.96M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.82M shares), Commodore Capital LP (3.45M shares), Bellevue Group AG (3.31M shares), Point72 Asset Management, L.P. (2.8M shares), and STATE STREET CORP (2.41M shares).
This table shows the top 178 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.